Browsing restrictions can be lifted for a fee.
Duogenic Stemcells Corp. engages in the provision of biotechnology and medical care services. It offers closed culture cell system and cell therapy services. The company was founded on March 22, 2018 and is headquartered in Taichung, Taiwan.
7607
通用幹細胞*
-1.13%
(-0.01)
The most recent financial report for 通用幹細胞* (7607) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating 7607's short-term business performance and financial health. For the latest updates on 7607's earnings releases, visit this page regularly.
At the end of the period, 通用幹細胞* (7607) held Total Cash and Cash Equivalents of 30.94M, accounting for 0.54 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
In the latest report, 通用幹細胞* (7607) did not achieve the “three margins increasing” benchmark, with a gross margin of 78.43%%, operating margin of -131.26%%, and net margin of -138.77%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess 7607's profit trajectory and future growth potential.